Company intelligence / Profile preview
DIMERx
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
DIMERx’s lead program, DMX‑101, has demonstrated safety, tolerability, and effectiveness in controlling abdominal pain and GI motility in a Phase 2 study among IBS-D patients. The company is advancing additional dimer candidates through IND-enabling studies. It recently secured global rights to a novel amino acid prodrug dimer from Massachusetts General Hospital for rare disease indications[4][5].
- Therapeutic areas
- NeurologyHematology
- Modalities
- Small moleculeChemical drugAmino acid dimer (prodrug)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Massachusetts General Hospital (exclusive patent license for amino acid prodrug dimers)[4][7]
Beyond the preview
Go deeper on DIMERx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIMERx.